ZP
CYTK icon

Zimmer Partners’s Cytokinetics CYTK Stock Holding History

Zimmer Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$2.75M – 135
2025
Q3 		$2.75M Sell
50,000
-26,500
-35% -$1.09M 0.06% 119
2025
Q2 		$2.53M Sell
76,500
-5,632
-7% -$196K 0.06% 130
2025
Q1 		$3.3M Buy
82,132
+44,132
+116% +$2.03M 0.06% 137
2024
Q4 		$1.79M Sell
38,000
-39,200
-51% -$2.04M 0.03% 133
2024
Q3 		$4.08M Sell
77,200
-15,000
-16% -$836K 0.07% 112
2024
Q2 		$5M Buy
92,200
+53,600
+139% +$3.24M 0.09% 109
2024
Q1 		$2.71M Buy
+38,600
New +$2.99M 0.06% 107
2023
Q3 		– Sell
-50,000
Closed -$1.63M – 131
2023
Q2 		$1.63M Buy
+50,000
New +$1.85M 0.04% 97

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Zimmer Partners's CYTK Position: Q4 2025 in Review

Zimmer Partners sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 50,000 shares — an estimated $2.75M sold.

Zimmer Partners first reported a position in CYTK in Q2 2023 and held it in 8 quarters. The position peaked at $5M in Q2 2024. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Zimmer Partners reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Zimmer Partners sold 50,000 Cytokinetics shares in Q4 2025, an estimated $2.75M.
  • Zimmer Partners first reported a position in Cytokinetics in Q2 2023 and held it in 8 quarters.
  • Zimmer Partners's Cytokinetics position peaked at $5M in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Zimmer Partners's 13F filing for Q4 2025, filed 17 Feb 2026.